TAM
DNLI icon

Tiverton Asset Management’s Denali Therapeutics DNLI Stock Holding History

Tiverton Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$66K Hold
4,276
– – ﹤0.01% 676
2019
Q2 		$89K Hold
4,276
– – ﹤0.01% 633
2019
Q1 		$99K Hold
4,276
– – ﹤0.01% 583
2018
Q4 		$88K Buy
+4,276
New +$77.6K 0.01% 388

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Tiverton Asset Management's DNLI Position: Q3 2019 in Review

Tiverton Asset Management held its Denali Therapeutics (DNLI) position steady in Q3 2019 at 4,276 shares worth $66K. The position accounts for ﹤0.01% of the portfolio, ranked #676.

Tiverton Asset Management first reported a position in DNLI in Q4 2018 and has held it in 4 quarters since. The position peaked at $99K in Q1 2019. 118 funds tracked by Wall St. Rank hold DNLI as of Q3 2019.

  • Tiverton Asset Management held 4,276 shares of Denali Therapeutics worth $66K as of Q3 2019.
  • Tiverton Asset Management left its Denali Therapeutics share count unchanged in Q3 2019.
  • Denali Therapeutics made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #676 holding.
  • Tiverton Asset Management first reported a position in Denali Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Tiverton Asset Management's Denali Therapeutics position peaked at $99K in Q1 2019.
  • 118 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.